Neurocrine Biosciences, Inc.San Diego, California, United States
Disclosure information not submitted.
SUN-468 - Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in Cahtalyst™ Adult Study
Sunday, June 14, 202612:00 PM - 1:30 PM CT
SUN-458 - Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the Cahtalyst™ Adult Study
Sunday, June 14, 20269:00 AM - 4:00 PM CT
ORF32-07 - Crinecerfont Improves Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst™ Adult Study
Sunday, June 14, 20262:55 PM - 3:10 PM CT
